COVID19
Serum, Bharat Biotech to work together to develop, supply COVID-19 vaccines
Serum Institute of India (SII) and Bharat Biotech on Tuesday said they will work together to develop, manufacture and supply the COVID-19 vaccines in India and globally. In a joint statement on behalf of the two companies, SII CEO Adar Poonawalla and Bharat Biotech Chairman and Managing Director Krishna Ella announced their combined intent to develop, manufacture and supply the COVID-19 vaccines for India and the world. They noted that the most important task in front of them was saving lives and livelihoods in India and globally.
Vaccines are global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest. Now that two COVID-19 vaccines have been issued EUA (emergency use authorisation) in India, the focus is on manufacturing, supply and distribution, such that population that need it the most receive high quality, safe and efficacious vaccines, the statement said. The DCGI on Sunday granted emergency use authorisation for Oxford-AstraZeneca’s Covishield and Bharat Biotech’s Covaxin. “Both our companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines. Each of our companies continue their COVID-19 vaccines development activities as planned,” the vaccine makers noted.
Also read: Access to foreign, Indian telecom gear source code to help govt check snooping: PHDCCI
“The companies are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our COVID-19 vaccines,” they added.
